SELUTION SLR™ DEB Wins US FDA Approval for In-Stent Restenosis - Cofounder Amit Bohora Calls It "A Defining Milestone for Stentless Cardiac Care"
Sep 25, 2026
San Francisco [US], September 25: The U.S. Food and Drug Administration has approved the SELUTION SLR™ (Sustained Limus Release) Drug-Eluting Balloon for coronary in-stent restenosis (ISR), Cordis announced this month - making it the first and only sirolimus drug-eluting balloon approved for use anywhere in the United States. For Amit Bohora, who co-founded MedAlliance and helped take SELUTION SLR from an early research concept to a globally commercialized therapy before the company was acquired by Cordis in October 2023 for USD 1.135 Billion, the approval is a personal milestone in a technology he spent over a decade building.
Read More...
